{"product_id":"triptorelin-acetate-10mg","title":"Triptorelin Acetate 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                    \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"678\" data-start=\"53\"\u003e\u003cstrong\u003eTriptorelin \u003c\/strong\u003eis a long-acting \u003cstrong data-end=\"169\" data-start=\"115\"\u003egonadotropin-releasing hormone (GnRH\/LHRH) agonist\u003c\/strong\u003e. After an initial \u003cstrong data-end=\"206\" data-start=\"188\"\u003eLH\/FSH “flare”\u003c\/strong\u003e, continued receptor stimulation on pituitary gonadotrophs causes \u003cstrong data-end=\"307\" data-start=\"272\"\u003edesensitization\/internalization\u003c\/strong\u003e and \u003cstrong data-end=\"327\" data-start=\"312\"\u003esuppression\u003c\/strong\u003e of gonadotropins, leading to \u003cstrong data-end=\"379\" data-start=\"357\"\u003emedical castration\u003c\/strong\u003e (↓ testosterone\/estradiol). It is widely approved for \u003cstrong data-end=\"462\" data-start=\"434\"\u003eadvanced prostate cancer\u003c\/strong\u003e, \u003cstrong data-end=\"500\" data-start=\"464\"\u003ecentral precocious puberty (CPP)\u003c\/strong\u003e, and (ex-US) \u003cstrong data-end=\"531\" data-start=\"514\"\u003eendometriosis\u003c\/strong\u003e, \u003cstrong data-end=\"553\" data-start=\"533\"\u003euterine fibroids\u003c\/strong\u003e, and \u003cstrong data-end=\"584\" data-start=\"559\"\u003eassisted reproduction\u003c\/strong\u003edown-regulation. Depot IM\/SC formulations (e.g., 1-, 3-, 6-month) provide sustained exposure.\u003c\/p\u003e\n\u003chr data-end=\"683\" data-start=\"680\"\u003e\n\u003ch3 data-end=\"747\" data-start=\"685\"\u003eAdditional Benefits of Triptorelin Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3169\" data-start=\"749\"\u003e\n\u003cthead data-end=\"777\" data-start=\"749\"\u003e\n\u003ctr data-end=\"777\" data-start=\"749\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"759\" data-start=\"749\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"777\" data-start=\"759\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3169\" data-start=\"788\"\u003e\n\u003ctr data-end=\"1090\" data-start=\"788\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"846\" data-start=\"788\"\u003e\u003cstrong data-end=\"845\" data-start=\"790\"\u003e1 Optimized prostate-cancer control in combinations\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1090\" data-start=\"846\"\u003eAs the ADT backbone, triptorelin pairs with \u003cstrong data-end=\"932\" data-start=\"892\"\u003eandrogen-receptor pathway inhibitors\u003c\/strong\u003e(abiraterone, apalutamide, enzalutamide, darolutamide) in mHSPC\/mCRPC to improve survival versus ADT alone. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;European Urology; Lancet Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1350\" data-start=\"1091\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1127\" data-start=\"1091\"\u003e\u003cstrong data-end=\"1126\" data-start=\"1093\"\u003e2 Intermittent ADT strategies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1350\" data-start=\"1127\"\u003eIntermittent triptorelin-based ADT can maintain disease control with \u003cstrong data-end=\"1224\" data-start=\"1198\"\u003ebetter quality of life\u003c\/strong\u003e in selected patients; ongoing work refines \u003cstrong data-end=\"1289\" data-start=\"1268\"\u003ePSA-based cycling\u003c\/strong\u003e criteria. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;NEJM; Journal of Clinical Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1604\" data-start=\"1351\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1391\" data-start=\"1351\"\u003e\u003cstrong data-end=\"1390\" data-start=\"1353\"\u003e3 Cardiometabolic risk management\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1604\" data-start=\"1391\"\u003ePrograms evaluate \u003cstrong data-end=\"1433\" data-start=\"1411\"\u003ebaselining CV risk\u003c\/strong\u003e, exercise\/nutrition, and statin\/SGLT2\/GLP-1RA co-therapy to mitigate \u003cstrong data-end=\"1532\" data-start=\"1503\"\u003eADT-related dysmetabolism\u003c\/strong\u003e while on triptorelin. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; JACC: CardioOncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1878\" data-start=\"1605\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1669\" data-start=\"1605\"\u003e\u003cstrong data-end=\"1668\" data-start=\"1607\"\u003e4 Ovarian function suppression (OFS) in HR+ breast cancer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1878\" data-start=\"1669\"\u003eIn premenopausal ER+ disease, triptorelin-based OFS plus tamoxifen or aromatase inhibitor \u003cstrong data-end=\"1795\" data-start=\"1761\"\u003eimproves disease-free survival\u003c\/strong\u003e versus endocrine therapy alone. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;NEJM; Journal of Clinical Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2141\" data-start=\"1879\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1930\" data-start=\"1879\"\u003e\u003cstrong data-end=\"1929\" data-start=\"1881\"\u003e5 Fertility preservation during chemotherapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2141\" data-start=\"1930\"\u003eTemporary ovarian suppression with triptorelin during cytotoxic therapy \u003cstrong data-end=\"2047\" data-start=\"2004\"\u003ereduces premature ovarian insufficiency\u003c\/strong\u003e and may \u003cstrong data-end=\"2099\" data-start=\"2056\"\u003eincrease post-treatment pregnancy rates\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JAMA; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2393\" data-start=\"2142\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2186\" data-start=\"2142\"\u003e\u003cstrong data-end=\"2185\" data-start=\"2144\"\u003e6 Endometriosis \u0026amp; adenomyosis control\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2393\" data-start=\"2186\"\u003e3–6 months of depot therapy \u003cstrong data-end=\"2259\" data-start=\"2216\"\u003ereduces pelvic pain and lesion activity\u003c\/strong\u003e; \u003cstrong data-end=\"2281\" data-start=\"2261\"\u003eadd-back therapy\u003c\/strong\u003e helps bone and vasomotor tolerability during prolonged courses. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Reproduction Update; BJOG\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2637\" data-start=\"2394\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2440\" data-start=\"2394\"\u003e\u003cstrong data-end=\"2439\" data-start=\"2396\"\u003e7 Uterine fibroids (pre-op or bridging)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2637\" data-start=\"2440\"\u003ePre-operative triptorelin \u003cstrong data-end=\"2509\" data-start=\"2468\"\u003eshrinks fibroids and improves anaemia\u003c\/strong\u003e, easing surgical approaches or bridging to definitive therapy. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Fertility and Sterility; Obstetrics \u0026amp; Gynecology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2928\" data-start=\"2638\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2670\" data-start=\"2638\"\u003e\u003cstrong data-end=\"2669\" data-start=\"2640\"\u003e8 IVF\/ART down-regulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2928\" data-start=\"2670\"\u003eLong-protocol down-regulation with triptorelin \u003cstrong data-end=\"2750\" data-start=\"2719\"\u003eprevents premature LH surge\u003c\/strong\u003e and can \u003cstrong data-end=\"2797\" data-start=\"2759\"\u003estandardize follicular recruitment\u003c\/strong\u003e; antagonist protocols now compete—comparative trials continue. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Reproductive BioMedicine Online; Human Reproduction\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3169\" data-start=\"2929\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2965\" data-start=\"2929\"\u003e\u003cstrong data-end=\"2964\" data-start=\"2931\"\u003e9 CPP convenience \u0026amp; adherence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3169\" data-start=\"2965\"\u003e\n\u003cstrong data-end=\"2984\" data-start=\"2967\"\u003e6-month depot\u003c\/strong\u003e schedules sustain \u003cstrong data-end=\"3023\" data-start=\"3003\"\u003eT\/E2 suppression\u003c\/strong\u003e with fewer injections and robust \u003cstrong data-end=\"3093\" data-start=\"3057\"\u003ebone-age\/height-velocity control\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Pediatrics; Journal of Clinical Endocrinology \u0026amp; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3174\" data-start=\"3171\"\u003e\n\u003ch2 data-end=\"3211\" data-start=\"3176\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3248\" data-start=\"3213\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3546\" data-start=\"3249\"\u003eTriptorelin binds \u003cstrong data-end=\"3288\" data-start=\"3267\"\u003eGnRH (GNRHR) GPCR\u003c\/strong\u003e on pituitary gonadotrophs → \u003cstrong data-end=\"3349\" data-start=\"3317\"\u003eGαq\/11–PLCβ–IP₃\/DAG–Ca²⁺\/PKC\u003c\/strong\u003e → acute \u003cstrong data-end=\"3376\" data-start=\"3358\"\u003eLH\/FSH release\u003c\/strong\u003e (“flare,” days 1–7). Continuous exposure triggers \u003cstrong data-end=\"3471\" data-start=\"3427\"\u003ereceptor desensitization\/internalization\u003c\/strong\u003e, suppressing LH\/FSH and downstream \u003cstrong data-end=\"3545\" data-start=\"3507\"\u003etesticular\/ovarian steroidogenesis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-end=\"3575\" data-start=\"3548\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3939\" data-start=\"3577\"\u003e\n\u003cthead data-end=\"3619\" data-start=\"3577\"\u003e\n\u003ctr data-end=\"3619\" data-start=\"3577\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3587\" data-start=\"3577\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3608\" data-start=\"3587\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3619\" data-start=\"3608\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3939\" data-start=\"3634\"\u003e\n\u003ctr data-end=\"3691\" data-start=\"3634\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3653\" data-start=\"3634\"\u003eIP₃\/Ca²⁺\/PKC→ERK\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3678\" data-start=\"3653\"\u003eAcute LH\/FSH secretion\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3691\" data-start=\"3678\"\u003ePituitary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3788\" data-start=\"3692\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3722\" data-start=\"3692\"\u003e↓ GnRH signalling (chronic)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3775\" data-start=\"3722\"\u003e↓ LHB\/FSHB transcription, gonadotropin suppression\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3788\" data-start=\"3775\"\u003ePituitary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3872\" data-start=\"3789\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3819\" data-start=\"3789\"\u003e↓ LH→Leydig \/ ↓ FSH→Sertoli\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3862\" data-start=\"3819\"\u003e↓ Testosterone; impaired spermatogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3872\" data-start=\"3862\"\u003eTestis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3939\" data-start=\"3873\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3890\" data-start=\"3873\"\u003e↓ LH\/FSH→Ovary\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3930\" data-start=\"3890\"\u003e↓ Estradiol\/progesterone; anovulation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3939\" data-start=\"3930\"\u003eOvary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3944\" data-start=\"3941\"\u003e\n\u003ch2 data-end=\"3968\" data-start=\"3946\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4506\" data-start=\"3970\"\u003e\n\u003cli data-end=\"4107\" data-start=\"3970\"\u003e\n\u003cp data-end=\"4107\" data-start=\"3972\"\u003e\u003cstrong data-end=\"3989\" data-start=\"3972\"\u003eFormulations:\u003c\/strong\u003e \u003cstrong data-end=\"4012\" data-start=\"3990\"\u003eMicrosphere depots\u003c\/strong\u003e (e.g., 3.75 mg q4wk; 11.25 mg q12wk; 22.5 mg q24wk) and pediatric \u003cstrong data-end=\"4096\" data-start=\"4079\"\u003e24-week depot\u003c\/strong\u003e for CPP.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4195\" data-start=\"4108\"\u003e\n\u003cp data-end=\"4195\" data-start=\"4110\"\u003e\u003cstrong data-end=\"4125\" data-start=\"4110\"\u003eAbsorption:\u003c\/strong\u003e Initial burst → sustained zero-order-like release from PLGA matrix.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4292\" data-start=\"4196\"\u003e\n\u003cp data-end=\"4292\" data-start=\"4198\"\u003e\u003cstrong data-end=\"4208\" data-start=\"4198\"\u003eOnset:\u003c\/strong\u003e \u003cstrong data-end=\"4228\" data-start=\"4209\"\u003eSteroid “flare”\u003c\/strong\u003e within first week; \u003cstrong data-end=\"4262\" data-start=\"4248\"\u003ecastrate T\u003c\/strong\u003e typically by \u003cstrong data-end=\"4289\" data-start=\"4276\"\u003e2–4 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4411\" data-start=\"4293\"\u003e\n\u003cp data-end=\"4411\" data-start=\"4295\"\u003e\u003cstrong data-end=\"4309\" data-start=\"4295\"\u003eHalf-life:\u003c\/strong\u003e Parent peptide t½ is short (hours) but \u003cstrong data-end=\"4371\" data-start=\"4349\"\u003eeffective duration\u003c\/strong\u003e reflects depot kinetics (1–6 months).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4506\" data-start=\"4412\"\u003e\n\u003cp data-end=\"4506\" data-start=\"4414\"\u003e\u003cstrong data-end=\"4428\" data-start=\"4414\"\u003eClearance:\u003c\/strong\u003e Peptidase degradation; renal\/hepatic peptide catabolism; no CYP interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4511\" data-start=\"4508\"\u003e\n\u003ch2 data-end=\"4558\" data-start=\"4513\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4600\" data-start=\"4560\"\u003e4.1 Prostate Cancer (ADT backbone)\u003c\/h3\u003e\n\u003cp data-end=\"4789\" data-start=\"4601\"\u003eTriptorelin achieves \u003cstrong data-end=\"4644\" data-start=\"4622\"\u003edurable castration\u003c\/strong\u003e with PSA responses comparable to other agonists; combinations with \u003cstrong data-end=\"4737\" data-start=\"4712\"\u003eAR pathway inhibitors\u003c\/strong\u003e significantly prolong \u003cstrong data-end=\"4771\" data-start=\"4760\"\u003erPFS\/OS\u003c\/strong\u003e versus ADT alone.\u003c\/p\u003e\n\u003ch3 data-end=\"4835\" data-start=\"4791\"\u003e4.2 Breast Cancer (premenopausal, HR+)\u003c\/h3\u003e\n\u003cp data-end=\"5017\" data-start=\"4836\"\u003eIn SOFT\/TEXT-style regimens, \u003cstrong data-end=\"4889\" data-start=\"4865\"\u003eOFS with triptorelin\u003c\/strong\u003e plus tamoxifen or an aromatase inhibitor \u003cstrong data-end=\"4974\" data-start=\"4931\"\u003eimproves invasive disease-free survival\u003c\/strong\u003e, particularly in \u003cstrong data-end=\"5007\" data-start=\"4992\"\u003ehigher-risk\u003c\/strong\u003e patients.\u003c\/p\u003e\n\u003ch3 data-end=\"5032\" data-start=\"5019\"\u003e4.3 CPP\u003c\/h3\u003e\n\u003cp data-end=\"5204\" data-start=\"5033\"\u003eDepot triptorelin \u003cstrong data-end=\"5086\" data-start=\"5051\"\u003esuppresses pubertal progression\u003c\/strong\u003e, \u003cstrong data-end=\"5118\" data-start=\"5088\"\u003enormalizes growth velocity\u003c\/strong\u003e, and \u003cstrong data-end=\"5159\" data-start=\"5124\"\u003eimproves predicted adult height\u003c\/strong\u003e, with convenient \u003cstrong data-end=\"5195\" data-start=\"5177\"\u003e6-month dosing\u003c\/strong\u003e options.\u003c\/p\u003e\n\u003ch3 data-end=\"5242\" data-start=\"5206\"\u003e4.4 Endometriosis\/Fibroids\/ART\u003c\/h3\u003e\n\u003cp data-end=\"5489\" data-start=\"5243\"\u003eIn endometriosis and fibroid protocols, triptorelin reduces \u003cstrong data-end=\"5331\" data-start=\"5303\"\u003eestrogen-driven activity\u003c\/strong\u003e, facilitating symptom control and surgery. In IVF, long down-regulation \u003cstrong data-end=\"5435\" data-start=\"5404\"\u003eprevents premature LH surge\u003c\/strong\u003e; antagonist regimens provide alternative flexibility.\u003c\/p\u003e\n\u003chr data-end=\"5494\" data-start=\"5491\"\u003e\n\u003ch2 data-end=\"5529\" data-start=\"5496\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6069\" data-start=\"5531\"\u003e\n\u003cthead data-end=\"5569\" data-start=\"5531\"\u003e\n\u003ctr data-end=\"5569\" data-start=\"5531\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5539\" data-start=\"5531\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5551\" data-start=\"5539\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5569\" data-start=\"5551\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6069\" data-start=\"5584\"\u003e\n\u003ctr data-end=\"5706\" data-start=\"5584\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5626\" data-start=\"5584\"\u003e\u003cstrong data-end=\"5625\" data-start=\"5586\"\u003eADT + cardiometabolic co-management\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5666\" data-start=\"5626\" data-col-size=\"md\"\u003eReduce CV events during long-term ADT\u003c\/td\u003e\n\u003ctd data-end=\"5706\" data-start=\"5666\" data-col-size=\"md\"\u003eProspective cardio-oncology programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5823\" data-start=\"5707\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5730\" data-start=\"5707\"\u003e\u003cstrong data-end=\"5729\" data-start=\"5709\"\u003eIntermittent ADT\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5783\" data-start=\"5730\" data-col-size=\"md\"\u003eQoL vs continuous ADT in mHSPC\/biochemical relapse\u003c\/td\u003e\n\u003ctd data-end=\"5823\" data-start=\"5783\" data-col-size=\"md\"\u003eOngoing refinement, patient-selected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5938\" data-start=\"5824\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5850\" data-start=\"5824\"\u003e\u003cstrong data-end=\"5849\" data-start=\"5826\"\u003eOFS personalization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5899\" data-start=\"5850\" data-col-size=\"md\"\u003eTailor duration\/intensity in HR+ breast cancer\u003c\/td\u003e\n\u003ctd data-end=\"5938\" data-start=\"5899\" data-col-size=\"md\"\u003eRisk-adapted strategies under study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6069\" data-start=\"5939\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5967\" data-start=\"5939\"\u003e\u003cstrong data-end=\"5966\" data-start=\"5941\"\u003eNon-binary\/trans care\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6016\" data-start=\"5967\" data-col-size=\"md\"\u003eGnRH analogs for puberty suppression\/adult OFS\u003c\/td\u003e\n\u003ctd data-end=\"6069\" data-start=\"6016\" data-col-size=\"md\"\u003ePractice varies by region; triptorelin used ex-US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6074\" data-start=\"6071\"\u003e\n\u003ch2 data-end=\"6105\" data-start=\"6076\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7040\" data-start=\"6107\"\u003e\n\u003cli data-end=\"6255\" data-start=\"6107\"\u003e\n\u003cp data-end=\"6255\" data-start=\"6109\"\u003e\u003cstrong data-end=\"6120\" data-start=\"6109\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-end=\"6136\" data-start=\"6121\"\u003eHot flashes\u003c\/strong\u003e, \u003cstrong data-end=\"6158\" data-start=\"6138\"\u003edecreased libido\u003c\/strong\u003e, \u003cstrong data-end=\"6191\" data-start=\"6160\"\u003eerectile\/sexual dysfunction\u003c\/strong\u003e, \u003cstrong data-end=\"6208\" data-start=\"6193\"\u003emood change\u003c\/strong\u003e, \u003cstrong data-end=\"6222\" data-start=\"6210\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-end=\"6252\" data-start=\"6224\"\u003einjection-site reactions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6442\" data-start=\"6256\"\u003e\n\u003cp data-end=\"6442\" data-start=\"6258\"\u003e\u003cstrong data-end=\"6277\" data-start=\"6258\"\u003eMetabolic\/Bone:\u003c\/strong\u003e \u003cstrong data-end=\"6293\" data-start=\"6278\"\u003eWeight gain\u003c\/strong\u003e, \u003cstrong data-end=\"6317\" data-start=\"6295\"\u003einsulin resistance\u003c\/strong\u003e, \u003cstrong data-end=\"6335\" data-start=\"6319\"\u003edyslipidemia\u003c\/strong\u003e, \u003cstrong data-end=\"6366\" data-start=\"6337\"\u003ebone-mineral density loss\u003c\/strong\u003e (consider \u003cstrong data-end=\"6384\" data-start=\"6377\"\u003eDXA\u003c\/strong\u003e and \u003cstrong data-end=\"6417\" data-start=\"6389\"\u003ebisphosphonate\/denosumab\u003c\/strong\u003e in long-term ADT\/OFS).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6633\" data-start=\"6443\"\u003e\n\u003cp data-end=\"6633\" data-start=\"6445\"\u003e\u003cstrong data-end=\"6474\" data-start=\"6445\"\u003eOn-treatment flare (men):\u003c\/strong\u003e Transient \u003cstrong data-end=\"6500\" data-start=\"6485\"\u003etumor-flare\u003c\/strong\u003e may cause \u003cstrong data-end=\"6570\" data-start=\"6511\"\u003ebone pain, urinary obstruction, spinal cord compression\u003c\/strong\u003e—use \u003cstrong data-end=\"6607\" data-start=\"6575\"\u003eantiandrogen lead-in\/overlap\u003c\/strong\u003e in metastatic settings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6769\" data-start=\"6634\"\u003e\n\u003cp data-end=\"6769\" data-start=\"6636\"\u003e\u003cstrong data-end=\"6646\" data-start=\"6636\"\u003eWomen:\u003c\/strong\u003e \u003cstrong data-end=\"6669\" data-start=\"6647\"\u003eVasomotor symptoms\u003c\/strong\u003e, \u003cstrong data-end=\"6685\" data-start=\"6671\"\u003eamenorrhea\u003c\/strong\u003e, initial \u003cstrong data-end=\"6712\" data-start=\"6695\"\u003eovarian cysts\u003c\/strong\u003e possible; use \u003cstrong data-end=\"6747\" data-start=\"6727\"\u003eadd-back therapy\u003c\/strong\u003e for longer courses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6886\" data-start=\"6770\"\u003e\n\u003cp data-end=\"6886\" data-start=\"6772\"\u003e\u003cstrong data-end=\"6787\" data-start=\"6772\"\u003ePediatrics:\u003c\/strong\u003e \u003cstrong data-end=\"6814\" data-start=\"6788\"\u003eInitial pubertal signs\u003c\/strong\u003e may transiently appear; monitor \u003cstrong data-end=\"6866\" data-start=\"6847\"\u003eheight velocity\u003c\/strong\u003e and \u003cstrong data-end=\"6883\" data-start=\"6871\"\u003ebone age\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7040\" data-start=\"6887\"\u003e\n\u003cp data-end=\"7040\" data-start=\"6889\"\u003e\u003cstrong data-end=\"6898\" data-start=\"6889\"\u003eRare:\u003c\/strong\u003e \u003cstrong data-end=\"6921\" data-start=\"6899\"\u003ePituitary apoplexy\u003c\/strong\u003e shortly after first dose in patients with undiagnosed adenomas; immediate evaluation if severe headache\/visual change.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7071\" data-start=\"7042\"\u003e\u003cstrong data-end=\"7071\" data-start=\"7042\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7610\" data-start=\"7073\"\u003e\n\u003cthead data-end=\"7196\" data-start=\"7073\"\u003e\n\u003ctr data-end=\"7196\" data-start=\"7073\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7083\" data-start=\"7073\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7116\" data-start=\"7083\"\u003e\u003cstrong data-end=\"7115\" data-start=\"7085\"\u003eTriptorelin (GnRH agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7162\" data-start=\"7116\"\u003e\u003cstrong data-end=\"7161\" data-start=\"7118\"\u003eGnRH antagonists (degarelix, relugolix)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7196\" data-start=\"7162\"\u003e\u003cstrong data-end=\"7194\" data-start=\"7164\"\u003eOrchiectomy \/ Oophorectomy\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7610\" data-start=\"7215\"\u003e\n\u003ctr data-end=\"7290\" data-start=\"7215\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7236\" data-start=\"7215\"\u003eOn-treatment flare\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7275\" data-start=\"7236\"\u003e\n\u003cstrong data-end=\"7245\" data-start=\"7238\"\u003eYes\u003c\/strong\u003e (mitigate with antiandrogen)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7284\" data-start=\"7275\"\u003e\u003cstrong data-end=\"7283\" data-start=\"7277\"\u003eNo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7290\" data-start=\"7284\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7358\" data-start=\"7291\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7312\" data-start=\"7291\"\u003eTime to castration\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7324\" data-start=\"7312\"\u003e2–4 weeks\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7345\" data-start=\"7324\"\u003e1–2 weeks (faster)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7358\" data-start=\"7345\"\u003eImmediate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7462\" data-start=\"7359\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7376\" data-start=\"7359\"\u003eCV risk signal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7392\" data-start=\"7376\"\u003eClass concern\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7435\" data-start=\"7392\"\u003eSome studies suggest \u003cstrong data-end=\"7434\" data-start=\"7415\"\u003elower CV events\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7462\" data-start=\"7435\"\u003eBaseline surgical risks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7555\" data-start=\"7463\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7477\" data-start=\"7463\"\u003eConvenience\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7503\" data-start=\"7477\"\u003eMonthly–6-monthly depot\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7533\" data-start=\"7503\"\u003eMonthly depot or daily oral\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7555\" data-start=\"7533\"\u003eOne-time procedure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7610\" data-start=\"7556\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7572\" data-start=\"7556\"\u003eReversibility\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7598\" data-start=\"7572\"\u003eYes (after depot wanes)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7604\" data-start=\"7598\"\u003eYes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7610\" data-start=\"7604\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7615\" data-start=\"7612\"\u003e\n\u003ch2 data-end=\"7643\" data-start=\"7617\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"8112\" data-start=\"7645\"\u003e\n\u003cli data-end=\"7732\" data-start=\"7645\"\u003e\n\u003cp data-end=\"7732\" data-start=\"7647\"\u003e\u003cstrong data-end=\"7660\" data-start=\"7647\"\u003eApproved:\u003c\/strong\u003e \u003cstrong data-end=\"7686\" data-start=\"7661\"\u003eProstate cancer (ADT)\u003c\/strong\u003e and \u003cstrong data-end=\"7698\" data-start=\"7691\"\u003eCPP\u003c\/strong\u003e (varies by region\/formulation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7825\" data-start=\"7733\"\u003e\n\u003cp data-end=\"7825\" data-start=\"7735\"\u003e\u003cstrong data-end=\"7757\" data-start=\"7735\"\u003eCommon ex-US uses:\u003c\/strong\u003e \u003cstrong data-end=\"7775\" data-start=\"7758\"\u003eEndometriosis\u003c\/strong\u003e, \u003cstrong data-end=\"7797\" data-start=\"7777\"\u003euterine fibroids\u003c\/strong\u003e, \u003cstrong data-end=\"7822\" data-start=\"7799\"\u003eART down-regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7950\" data-start=\"7826\"\u003e\n\u003cp data-end=\"7950\" data-start=\"7828\"\u003e\u003cstrong data-end=\"7843\" data-start=\"7828\"\u003eMonitoring:\u003c\/strong\u003e For ADT\/OFS, monitor \u003cstrong data-end=\"7880\" data-start=\"7865\"\u003eT\/E2 levels\u003c\/strong\u003e, \u003cstrong data-end=\"7901\" data-start=\"7882\"\u003emetabolic panel\u003c\/strong\u003e, \u003cstrong data-end=\"7910\" data-start=\"7903\"\u003eBMD\u003c\/strong\u003e, and disease markers (e.g., \u003cstrong data-end=\"7946\" data-start=\"7939\"\u003ePSA\u003c\/strong\u003e).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8112\" data-start=\"7951\"\u003e\n\u003cp data-end=\"8112\" data-start=\"7953\"\u003e\u003cstrong data-end=\"7975\" data-start=\"7953\"\u003eContraindications:\u003c\/strong\u003e Pregnancy, breastfeeding, hypersensitivity to GnRH analogs; caution in \u003cstrong data-end=\"8070\" data-start=\"8047\"\u003esevere osteoporosis\u003c\/strong\u003eand \u003cstrong data-end=\"8098\" data-start=\"8075\"\u003eunstable metastases\u003c\/strong\u003e (flare risk).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8117\" data-start=\"8114\"\u003e\n\u003ch2 data-end=\"8142\" data-start=\"8119\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8673\" data-start=\"8144\"\u003e\n\u003cli data-end=\"8233\" data-start=\"8144\"\u003e\n\u003cp data-end=\"8233\" data-start=\"8146\"\u003e\u003cstrong data-end=\"8167\" data-start=\"8146\"\u003eDepot innovation:\u003c\/strong\u003e Longer-acting and smaller-volume depots; \u003cstrong data-end=\"8230\" data-start=\"8209\"\u003eSC auto-injectors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8363\" data-start=\"8234\"\u003e\n\u003cp data-end=\"8363\" data-start=\"8236\"\u003e\u003cstrong data-end=\"8258\" data-start=\"8236\"\u003ePrecision ADT\/OFS:\u003c\/strong\u003e \u003cstrong data-end=\"8285\" data-start=\"8259\"\u003eRisk-adapted durations\u003c\/strong\u003e, \u003cstrong data-end=\"8307\" data-start=\"8287\"\u003ebiomarker-guided\u003c\/strong\u003e restart\/stop rules (PSA kinetics, ultrasensitive E2).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8458\" data-start=\"8364\"\u003e\n\u003cp data-end=\"8458\" data-start=\"8366\"\u003e\u003cstrong data-end=\"8395\" data-start=\"8366\"\u003eCardio-oncology pathways:\u003c\/strong\u003e Integrated \u003cstrong data-end=\"8429\" data-start=\"8407\"\u003eCV risk mitigation\u003c\/strong\u003e embedded in ADT protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8575\" data-start=\"8459\"\u003e\n\u003cp data-end=\"8575\" data-start=\"8461\"\u003e\u003cstrong data-end=\"8484\" data-start=\"8461\"\u003eCombination trials:\u003c\/strong\u003e Triplet regimens (\u003cstrong data-end=\"8528\" data-start=\"8503\"\u003eADT + ARSI + RT\/chemo\u003c\/strong\u003e) and \u003cstrong data-end=\"8551\" data-start=\"8534\"\u003ede-escalation\u003c\/strong\u003e after deep responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8673\" data-start=\"8576\"\u003e\n\u003cp data-end=\"8673\" data-start=\"8578\"\u003e\u003cstrong data-end=\"8596\" data-start=\"8578\"\u003ePediatric CPP:\u003c\/strong\u003e Long-term \u003cstrong data-end=\"8634\" data-start=\"8607\"\u003eneurocognitive and bone\u003c\/strong\u003e outcomes with extended 6-month dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8678\" data-start=\"8675\"\u003e\n\u003ch3 data-end=\"8703\" data-start=\"8680\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9481\" data-start=\"8705\"\u003e\n\u003cli data-end=\"8805\" data-start=\"8705\"\u003e\n\u003cp data-end=\"8805\" data-start=\"8707\"\u003e\u003cem data-end=\"8742\" data-start=\"8707\"\u003eEuropean Urology; Lancet Oncology\u003c\/em\u003e — ADT backbones and AR-targeted combinations in mHSPC\/mCRPC.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8947\" data-start=\"8806\"\u003e\n\u003cp data-end=\"8947\" data-start=\"8808\"\u003e\u003cem data-end=\"8871\" data-start=\"8808\"\u003eNew England Journal of Medicine; Journal of Clinical Oncology\u003c\/em\u003e — Intermittent vs continuous ADT; OFS in premenopausal HR+ breast cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9048\" data-start=\"8948\"\u003e\n\u003cp data-end=\"9048\" data-start=\"8950\"\u003e\u003cem data-end=\"8976\" data-start=\"8950\"\u003eJAMA; Annals of Oncology\u003c\/em\u003e — Ovarian suppression during chemotherapy and fertility preservation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9166\" data-start=\"9049\"\u003e\n\u003cp data-end=\"9166\" data-start=\"9051\"\u003e\u003cem data-end=\"9084\" data-start=\"9051\"\u003eHuman Reproduction Update; BJOG\u003c\/em\u003e — Endometriosis\/adenomyosis management with GnRH agonists and add-back therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9298\" data-start=\"9167\"\u003e\n\u003cp data-end=\"9298\" data-start=\"9169\"\u003e\u003cem data-end=\"9219\" data-start=\"9169\"\u003eFertility and Sterility; Obstetrics \u0026amp; Gynecology\u003c\/em\u003e — Uterine fibroid pre-operative shrinkage and ART down-regulation protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9393\" data-start=\"9299\"\u003e\n\u003cp data-end=\"9393\" data-start=\"9301\"\u003e\u003cem data-end=\"9319\" data-start=\"9301\"\u003ePediatrics; JCEM\u003c\/em\u003e — CPP efficacy, growth and bone-age outcomes with long-interval depots.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9481\" data-start=\"9394\"\u003e\n\u003cp data-end=\"9481\" data-start=\"9396\"\u003e\u003cem data-end=\"9431\" data-start=\"9396\"\u003eCirculation; JACC: CardioOncology\u003c\/em\u003e — Cardiometabolic risk and mitigation during ADT\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684853870930,"sku":null,"price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/triptorelin_acetate_10mg.png?v=1770834870","url":"https:\/\/sciencepeptideslab.com\/products\/triptorelin-acetate-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}